X4 Pharmaceuticals (XFOR) Misses Q2 EPS by 17c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of ($0.33), $0.17 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $-55.7 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance